Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.
Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath CA 3rd, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Al Baghdadi T, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. Eskander RN, et al. Among authors: cantuaria gh. N Engl J Med. 2023 Jun 8;388(23):2159-2170. doi: 10.1056/NEJMoa2302312. Epub 2023 Mar 27. N Engl J Med. 2023. PMID: 36972022 Free PMC article. Clinical Trial.
Epithelial ovarian cancer: An overview.
Desai A, Xu J, Aysola K, Qin Y, Okoli C, Hariprasad R, Chinemerem U, Gates C, Reddy A, Danner O, Franklin G, Ngozi A, Cantuaria G, Singh K, Grizzle W, Landen C, Partridge EE, Rice VM, Reddy ES, Rao VN. Desai A, et al. World J Transl Med. 2014 Apr 12;3(1):1-8. doi: 10.5528/wjtm.v3.i1.1. World J Transl Med. 2014. PMID: 25525571 Free PMC article.
Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008).
Santin AD, Filiaci V, Bellone S, Ratner ES, Mathews CA, Cantuaria G, Gunderson CC, Rutledge T, Buttin BM, Lankes HA, Frumovitz M, Khleif SN, Huh WK, Birrer MJ. Santin AD, et al. Gynecol Oncol Rep. 2020 Jan 2;31:100532. doi: 10.1016/j.gore.2019.100532. eCollection 2020 Feb. Gynecol Oncol Rep. 2020. PMID: 31934607 Free PMC article.
Corrigendum to "Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)" [Gynecol. Oncol. Rep. 31 (2020) 100532].
Santin AD, Filiaci V, Bellone S, O'Cearbhaill R, Ratner ES, Mathews CA, Cantuaria G, Gunderson CC, Rutledge T, Buttin BM, Lankes HA, Birrer MJ. Santin AD, et al. Gynecol Oncol Rep. 2020 May 28;33:100590. doi: 10.1016/j.gore.2020.100590. eCollection 2020 Aug. Gynecol Oncol Rep. 2020. PMID: 32885014 Free PMC article.
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA; RUBY Investigators. Mirza MR, et al. N Engl J Med. 2023 Jun 8;388(23):2145-2158. doi: 10.1056/NEJMoa2216334. Epub 2023 Mar 27. N Engl J Med. 2023. PMID: 36972026 Clinical Trial.
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.
Lee JM, Brady MF, Miller A, Moore RG, MacKay H, McNally L, Lea J, Street D, Lheureux S, McDonald ME, Duska LR, Cantuaria G, Kavecansky J, Leath CA 3rd, Powell M, Cadungog MG, Rose PG, Kim YM, Huang HQ, Provencher M, Wenzel LB, Bookman MA, Kohn EC, Secord AA. Lee JM, et al. J Clin Oncol. 2024 Oct 3:JCO2400683. doi: 10.1200/JCO.24.00683. Online ahead of print. J Clin Oncol. 2024. PMID: 39361946
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
Vergote I, Ray-Coquard I, Anderson DM, Cantuaria G, Colombo N, Garnier-Tixidre C, Gilbert L, Harter P, Hettle R, Lorusso D, Mäenpää J, Marth C, Matsumoto K, Ouwens M, Poveda A, Raspagliesi F, Rhodes K, Rubio Pérez MJ, Shapira-Frommer R, Shikama A, Sikorska M, Moore K, DiSilvestro P. Vergote I, et al. Eur J Cancer. 2021 Nov;157:415-423. doi: 10.1016/j.ejca.2021.08.023. Epub 2021 Sep 28. Eur J Cancer. 2021. PMID: 34597975 Free article. Clinical Trial.
Guiding Lay Navigation in Geriatric Patients With Cancer Using a Distress Assessment Tool.
Rocque GB, Taylor RA, Acemgil A, Li X, Pisu M, Kenzik K, Jackson BE, Halilova KI, Demark-Wahnefried W, Meneses K, Li Y, Martin MY, Chambless C, Lisovicz N, Fouad M, Partridge EE, Kvale EA; Patient Care Connect Group. Rocque GB, et al. J Natl Compr Canc Netw. 2016 Apr;14(4):407-14. doi: 10.6004/jnccn.2016.0047. J Natl Compr Canc Netw. 2016. PMID: 27059189 Free PMC article.
Preclinical Development of a Nontoxic Oral Formulation of Monoethanolamine, a Lipid Precursor, for Prostate Cancer Treatment.
Saxena R, Yang C, Rao M, Turaga RC, Garlapati C, Gundala SR, Myers K, Ghareeb A, Bhattarai S, Kamalinia G, Bristi S, Su D, Gadda G, Rida PCG, Cantuaria GH, Aneja R. Saxena R, et al. Among authors: cantuaria gh. Clin Cancer Res. 2017 Jul 15;23(14):3781-3793. doi: 10.1158/1078-0432.CCR-16-1716. Epub 2017 Feb 6. Clin Cancer Res. 2017. PMID: 28167510 Free PMC article.
25 results